2024
The influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users
Lazorwitz A, Sheeder J, Teal S. The influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users. Contraception 2024, 110539. PMID: 39002624, DOI: 10.1016/j.contraception.2024.110539.Peer-Reviewed Original ResearchContraceptive implant usersSerum etonogestrel concentrationsEtonogestrel concentrationsImplant usersEtonogestrel implant usersSteady-state pharmacokineticsLifestyle factorsIncreased caloric intakeInfluence of lifestyle factorsCaloric intakeSubstance useCross-sectional analysisEtonogestrelCurrent dietInconsistent associationsExercise habitsAssociationDietPharmacokineticsExerciseSerumSurvey responsesIntake
2023
An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users
Diamond B, Sheeder J, Lazorwitz A. An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users. Contraception 2023, 129: 110298. PMID: 37802462, PMCID: PMC10842501, DOI: 10.1016/j.contraception.2023.110298.Peer-Reviewed Original ResearchConceptsMood-related side effectsContraceptive implant usersENG implant usersInter-individual variabilitySide effectsImplant usersEtonogestrel contraceptive implant usersMood changesWide inter-individual variabilitySerum etonogestrel concentrationsPHQ-9 scoresSerum drug levelsLiquid chromatography-mass spectrometry assaySubset of participantsEtonogestrel concentrationsPrimary outcomePharmacokinetic variabilityMood concernsBaseline questionnairePHQ-9Blood drawDrug levelsMood symptomsImplant usePossible associationThe effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study
Lazorwitz A, Sheeder J, Teal S. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study. Contraception 2023, 123: 110035. PMID: 36997081, PMCID: PMC10461170, DOI: 10.1016/j.contraception.2023.110035.Peer-Reviewed Original ResearchConceptsContraceptive implant usersSerum etonogestrel concentrationsStrong CYP3A inducersENG implant usersEtonogestrel concentrationsMedian ageImplant usersCYP3A inducersP4 concentrationsMedian body mass indexSerum E2 concentrationsBody mass indexSignificant decreaseParticipants' median ageSuppression of ovulationSerum P4 concentrationsEffect of rifampinDrug-drug interactionsLiquid chromatography-mass spectrometry assayOnly short exposuresWilcoxon signed-rank testBaseline E2Rifampin 600Rifampin exposureRifampin therapy
2022
P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer
Lazorwitz A, Teal S, Sheeder J. P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer. Contraception 2022, 116: 92. DOI: 10.1016/j.contraception.2022.09.103.Peer-Reviewed Original ResearchStrong CYP3A inducersBreakthrough ovulationCYP3A inducersE2 concentrationsP4 concentrationsMedian ageOvulation suppressionImplant usersPg/Baseline serum concentrationsContraceptive implant usersEtonogestrel implant usersSerum E2 concentrationsParticipants' median ageSerum P4 concentrationsENG implant usersDrug-drug interactionsRifampin exposureMedian durationENG implantMedian BMIEndogenous estradiolSerum concentrationsSurrogate biomarkerWeeks of exposureEffect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users
Lazorwitz A, Pena M, Sheeder J, Teal S. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2022, 139: 579-587. PMID: 35594123, PMCID: PMC9140306, DOI: 10.1097/aog.0000000000004697.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsBody mass indexPg/Median ageImplant usersEnzyme-inducing antiepileptic drugsMedian body mass indexEffects of topiramateMean percent changeParticipants' median ageOvulatory suppressionTopiramate therapyMedian durationTopiramate useEtonogestrel implantsPharmacokinetic interactionsHealthy womenAntiepileptic drugsMass indexNoninferiority studyImplant useMass spectrometry assayPercent change
2021
Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period
Lazorwitz A, Sheeder J, Teal S. Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period. Contraception 2021, 108: 65-68. PMID: 34973207, PMCID: PMC9011406, DOI: 10.1016/j.contraception.2021.12.008.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsImplant usersEtonogestrel implant usersSingle-time measurementsEtonogestrel implantsPharmacokinetic outcomesRepeated measures testSmall studyPharmacokinetic measurementsTime pointsPharmacokinetic studyConfidence intervalsMeasures studyImplant studiesMeasures testEtonogestrelPOSTER ABSTRACTS P58 THE EFFECT OF TOPIRAMATE ON ETONOGESTREL CONCENTRATIONS IN CONTRACEPTIVE IMPLANT USERS
Lazorwitz A, Peña M, Sheeder J, Teal S. POSTER ABSTRACTS P58 THE EFFECT OF TOPIRAMATE ON ETONOGESTREL CONCENTRATIONS IN CONTRACEPTIVE IMPLANT USERS. Contraception 2021, 104: 465. DOI: 10.1016/j.contraception.2021.07.076.Peer-Reviewed Original ResearchEtonogestrel contraceptive implant uptake and safety among solid organ transplant recipients
Lew J, Sheeder J, Lazorwitz A. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients. Contraception 2021, 104: 556-560. PMID: 34147509, PMCID: PMC8502202, DOI: 10.1016/j.contraception.2021.06.007.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsReproductive-age womenEtonogestrel contraceptive implantContraceptive implant usersTransplant recipientsContraceptive implantsCommon transplant-related complicationPost-transplant infectionsSafe contraceptive optionTransplant-related outcomesRetrospective cohort studyTransplant-related complicationsGraft-related complicationsSide effect profileTertiary medical centerRisk of pregnancyImplant usersContraceptive implant useAdditional health risksPregnancy patternsCohort studyGraft complicationsGraft rejectionEffect profileApplicability of ancestral genotyping in pharmacogenomic research with hormonal contraception
Lazorwitz A, Aquilante C, Shortt J, Sheeder J, Teal S, Gignoux C. Applicability of ancestral genotyping in pharmacogenomic research with hormonal contraception. Clinical And Translational Science 2021, 14: 1713-1718. PMID: 33650294, PMCID: PMC8504805, DOI: 10.1111/cts.13014.Peer-Reviewed Original ResearchConceptsSelf-reported race/ethnicityHispanic/Latina ethnicityRace/ethnicityContraceptive implant usersSerum etonogestrel concentrationsEtonogestrel concentrationsLatina ethnicitySide effectsBlack/African American raceImplant usersSelf-reported black raceReproductive-aged womenNon-Hispanic raceMultivariable logistic regressionAfrican American racePharmacodynamics/pharmacokineticsHormonal contraceptionPharmacodynamic outcomesBlack raceAn exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users
Lazorwitz A, Sheeder J, Teal S. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users. The European Journal Of Contraception & Reproductive Health Care 2021, 26: 323-325. PMID: 33596152, PMCID: PMC8496990, DOI: 10.1080/13625187.2021.1887475.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsExercise habitsImplant usersStanford Brief Activity SurveySteady-state pharmacokineticsReproductive-age womenLiquid chromatography-mass spectrometry assayEtonogestrel implantsLifestyle factorsSedentary lifestyleMass spectrometry assaySecondary analysisSignificant associationVital signsActivity SurveyDietAssociationExploratory studyInconsistent effectsHabitsParticipantsPharmacokineticsSurvey responses
2020
An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users
Lazorwitz A, Dindinger E, Harrison M, Aquilante C, Sheeder J, Teal S. An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Contraception 2020, 102: 180-185. PMID: 32407811, PMCID: PMC7483263, DOI: 10.1016/j.contraception.2020.05.002.Peer-Reviewed Original ResearchConceptsBody mass indexEtonogestrel contraceptive implant usersEstrogen receptor 1Contraceptive implant usersContraceptive implant useWeight gainImplant useWeight changeImplant insertionEnrollment body mass indexMedian body mass indexGenetic variantsReproductive-aged womenMedian weight changeImplant usersExogenous steroid hormonesEstrogen receptor 1 geneReceptor 1 genePhysiologic plausibilityEtonogestrel implantsMetabolic syndromeMedical recordsContraceptive counselingRetrospective analysisIndividualized counselingA pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Seale R, Davis A, Guiahi M. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users. Contraception 2020, 102: 58-60. PMID: 32325076, PMCID: PMC7272275, DOI: 10.1016/j.contraception.2020.04.011.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsReproductive-age womenOvulatory suppressionContraceptive implantsImplant usersHealthy reproductive-age womenEffect of isotretinoinEtonogestrel contraceptive implantIsotretinoin therapyPharmacokinetic interactionsReliable contraceptionIsotretinoinSmall studyPilot studyPotent teratogenBaselineWomenSignificant changesAppropriate optionImplantsEtonogestrelPatientsPregnancy
2019
Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users.
Lazorwitz A, Aquilante C, Dindinger E, Harrison M, Sheeder J, Teal S. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users. Obstetrics And Gynecology 2019, 134: 807-813. PMID: 31503152, PMCID: PMC6768730, DOI: 10.1097/aog.0000000000003452.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsOral contraceptive pillsRelated side effectsAbnormal bleedingSide effectsBleeding patternsContraceptive pillsContraceptive implantsBothersome bleedingImplant usersProspective cross-sectional studyReproductive-aged womenMultivariable logistic regressionHormonal contraceptive methodsCross-sectional studyDiscontinuation ratesEtonogestrel implantsPatient satisfactionPill prescriptionMedical recordsBleedingContraceptive methodsImplant useRelationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Aquilante C, Sheeder J, Guiahi M, Teal S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception 2019, 100: 37-41. PMID: 30980827, PMCID: PMC6589369, DOI: 10.1016/j.contraception.2019.03.045.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersBody mass indexBlack/African American raceEtonogestrel concentrationsAfrican American raceMass indexPatient characteristicsImplant useEtonogestrel levelsImplant usersAmerican raceHispanic/Latina ethnicityMedian body mass indexSerum etonogestrel levelsEtonogestrel contraceptive implantSide effect profileReproductive-age womenCertain patient characteristicsIndividual patient characteristicsMajority of womenNon-significant increaseLatina ethnicityMedian ageSerum concentrationsInfluence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.
Lazorwitz A, Aquilante C, Oreschak K, Sheeder J, Guiahi M, Teal S. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2019, 133: 783-794. PMID: 30870275, PMCID: PMC6448146, DOI: 10.1097/aog.0000000000003189.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsBody mass indexContraceptive implant usersEtonogestrel concentrationsSteroid hormone metabolismImplant useGenetic variantsHepatic enzyme inducersReproductive-age womenImplant usersHormone metabolismPersonalized medicine approachVariant allele frequencyOvulatory suppressionEtonogestrel implantsMass indexHormonal contraceptionConcomitant useWomen's healthPg/Medicine approachParticipant characteristicsSteroid hormonesEnzyme inducersPharmacogenomic investigations
2017
The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. Contraception 2017, 95: 571-577. PMID: 28288788, DOI: 10.1016/j.contraception.2017.03.004.Peer-Reviewed Original ResearchConceptsEtonogestrel concentrationsEtonogestrel contraceptive implantCarbamazepine coadministrationFollicle-like structuresOvulatory suppressionEndometrial thicknessMean ageContraceptive implantsPg/Contraceptive implant usersEtonogestrel implant usersSerum etonogestrel concentrationsReproductive-age womenBody mass indexRisk of pregnancyEffects of carbamazepineImplant usersParticipants' mean ageImpact of carbamazepineEtonogestrel levelsMedian durationPharmacodynamic changesTransvaginal ultrasoundMajority of participantsMass index